Results 151 to 160 of about 1,285,117 (188)
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Background The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common.
Oliver Rees +5 more
wiley +1 more source
Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1
Pacing and Clinical Electrophysiology, EarlyView.Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino +3 more
wiley +1 more source
Experimental Physiology, EarlyView.Abstract Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides ...
Julio Flores +4 more
wiley +1 more source
Glucocorticoids modulate drug transporter function in human fetal brain endothelial cells
The Journal of Physiology, EarlyView.Abstract figure legend P‐glycoprotein and breast cancer resistance protein are the most prominent drug transporters at the fetal blood–brain barrier. We isolated primary human fetal brain endothelial cells from early and mid‐gestation cerebral microvessels and exposed them to glucocorticoids cortisol and dexamethasone in vitro.
Nikola Ivanovski +3 more
wiley +1 more source
On the importance of including both sexes in animal studies – insights from home‐cage monitoring
Biological Reviews, Volume 101, Issue 5, Page 2408-2426, October 2026.ABSTRACT A review of behavioural studies using home‐cage monitoring (HCM) systems revealed that over 61% of studies used only male subjects, with only 24% including both sexes, despite evidence of substantial behavioural differences between male and female animals. This bias could influence the outcomes of biomedical research.
Maša Čater +12 more
wiley +1 more source
SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9412-9422, October 2026.ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu +20 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez +13 more
wiley +1 more source